Last 24 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.81 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.49 | 1.38 | 4.78 | 2.23 | 1.26 | 0.76 | 0.64 | 0.64 | 1.88 | 1.09 | 2.61 | 1.52 | 1.31 | 1.06 | 0.31 | 0.30 | 0.47 | 0.81 | 0.76 | 0.56 | — |
| — | +82.8% | +646.1% | +246.9% | -33.0% | -30.8% | -75.5% | -57.6% | +43.4% | +2.7% | +735.3% | +407.7% | +181.7% | +30.9% | -59.1% | -46.8% | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -46.4% | -32.2% | -15.4% | -19.5% | -12.4% | -10.2% | -4.9% | -3.7% | -18.9% | -4.1% | -36.1% | -44.8% | -27.7% | -19.0% | -19.9% | -9.8% | -9.7% | -9.2% | -7.3% | -24.7% | — |
| — | -216.7% | -213.5% | -422.2% | +34.1% | -147.2% | +86.4% | +91.7% | +31.9% | +78.3% | -81.7% | -358.2% | -186.7% | -107.5% | -170.7% | +60.4% | — | — | — | — | — | |
| ROA | -43.4% | -27.7% | -13.6% | -17.6% | -11.7% | -9.8% | -4.8% | -3.6% | -18.5% | -4.0% | -27.1% | -34.7% | -23.2% | -16.8% | -18.0% | -8.9% | -8.9% | -8.7% | -7.0% | -11.5% | -58.0% |
| — | -182.9% | -184.6% | -386.5% | +36.9% | -147.3% | +82.3% | +89.5% | +20.2% | +76.4% | -50.0% | -290.2% | -160.6% | -93.1% | -158.0% | +23.0% | +84.7% | +95.7% | +89.3% | +93.1% | — | |
| ROIC | — | — | — | — | — | -1436.8% | -288.0% | -1815.0% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
| — | +216.6% | +154.1% | -19.5% | -34.2% | — | — | — | — | — | — | — | — | -86.3% | -59.5% | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 8.52 | 5.81 | 8.96 | 8.52 | 13.07 | 19.09 | 48.80 | 35.62 | 36.91 | 64.01 | 4.23 | 3.83 | 4.99 | 7.37 | 9.86 | 11.80 | 10.45 | 14.64 | 29.16 | 16.90 | 0.10 |
| — | -69.6% | -81.6% | -76.1% | -64.6% | -70.2% | +1053.2% | +830.4% | +639.7% | +768.0% | -57.1% | -67.6% | -52.3% | -49.6% | -66.2% | -30.2% | +10434.2% | +4355.4% | +5729.3% | +53795.9% | — | |
| Quick Ratio | 8.52 | 5.81 | 8.96 | 8.52 | 13.07 | 19.09 | 48.80 | 35.62 | 36.91 | 64.01 | 4.23 | 3.83 | 4.99 | 7.37 | 9.86 | 11.80 | 10.45 | 14.64 | 29.16 | 16.90 | 0.10 |
| — | -69.6% | -81.6% | -76.1% | -64.6% | -70.2% | +1053.2% | +830.4% | +639.7% | +768.0% | -57.1% | -67.6% | -52.3% | -49.6% | -66.2% | -30.2% | +10434.2% | +4355.4% | +5729.3% | +53795.9% | — | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -1243.51 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 24 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CNTX stock.
Context Therapeutics Inc.'s current P/E is -0.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Context Therapeutics Inc.'s business trajectory between earnings reports.